CoChat

AAVs Anatomy: Roadmap for Optimizing Vectors for Translational Success

Open access
M. Mitchell, Angela, C. Nicolson, Sarah, K. Warischalk, Jayme, Jude Samulski, R. · 2010 · Current Gene Therapy
Cited by 96

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

Abstract

Adeno-Associated Virus based vectors (rAAV) are advantageous for human gene therapy due to low inflammatory responses, lack of toxicity, natural persistence, and ability to transencapsidate the genome allowing large variations in vector biology and tropism. Over sixty clinical trials have been conducted using rAAV serotype 2 for gene delivery with a number demonstrating success in immunoprivileged sites, including the retina and the CNS. Furthermore, an increasing number of trials have been initiated utilizing other serotypes of AAV to exploit vector tropism, trafficking, and expression efficiency. While these trials have demonstrated success in safety with emerging success in clinical outcomes, one benefit has been identification of issues associated with vector administration in humans (e.g. the role of pre-existing antibody responses, loss of transgene expression in non-immunoprivileged sites, and low transgene expression levels). For these reasons, several strategies are being used to optimize rAAV vectors, ranging from addition of exogenous agents for immune evasion to optimization of the transgene cassette for enhanced therapeutic output. By far, the vast majority of approaches have focused on genetic manipulation of the viral capsid. These methods include rational mutagenesis, engineering of targeting peptides, generation of chimeric particles, library and directed evolution approaches, as well as immune evasion modifications. Overall, these modifications have created a new repertoire of AAV vectors with improved targeting, transgene expression, and immune evasion. Continued work in these areas should synergize strategies to improve capsids and transgene cassettes that will eventually lead to optimized vectors ideally suited for translational success. Keywords: Adeno-associated virus, clinical trials, directed evolution, gene delivery, immune response, capsid modification, targeting, AAV's Anatomy, rAAV, capsid modification targeting, Gene therapy, RNAs, virus-like particles, PEGylation, Bactofection, Baculoviruses, bacteriophage, Herpes Simplex Virus, Adenovirus, Reoviruses, Vesicular Stomatitis Virus, Measles Virus, cancer immunotherapy, X-linked adrenoleukodystrophy, Parvoviridae, Dependovirus, Inverted terminal repeats, Vac-cinia virus, Human Papillomavirus, Cystic Fibrosis, CFTR, Hemophilia B, Le-ber Congenital Amerosis type 2, RPE65 gene, CNS, Canavan disease, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, choroderaemia, epilepsy, GABA, GDNF, melanoma, carcinoma, muscular dystrophy, Vector Tropism, biopanning, avadin affinity chromatography, PCR, blood brain barrier, HPMA, hTERT, glucose transporter isoform 1, neoantigen, Capsid Topology, Transencapsidated Vectors

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/156652310793180706

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 67 references

Cited by

See all 96

Metadata

Authors
M. Mitchell, A., C. Nicolson, S., K. Warischalk, J., & Jude Samulski, R.
Venue
Current Gene Therapy
Published
2010-10-01
Volume
10
Issue
5
Pages
319-340
ISSN
1566-5232 (ISSN-L)
OpenAlex
W2052219470
Cited by
96
References
67
FWCI
6.54
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: AAVs Anatomy: Roadmap for Optimizing Vectors for Translational Success. https://app.cochat.ai/papers/10.2174/156652310793180706
The paper
M. Mitchell, A., C. Nicolson, S., K. Warischalk, J., & Jude Samulski, R. (2010). AAVs Anatomy: Roadmap for Optimizing Vectors for Translational Success. Current Gene Therapy. https://doi.org/10.2174/156652310793180706

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.